Eli Lilly bids to stop generics cutting Alimta exclusivity

23-08-2013

Eli Lilly bids to stop generics cutting Alimta exclusivity

Eli Lilly has begun its defence of a patent covering lung cancer drug Alimta against generic companies including Teva, Barr Laboratories and APP Pharmaceuticals.


Eli Lilly, Teva, Barr, APP, Alimta

LSIPR